Promega Corporation

A Fully Automated Platform For Drug Metabolism Profiling Poster




Tracy Worzella1, Brad Larson1, Gerlinde Zerza-Schnitzhofer2, and Siegfried Sasshofer2
1Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711
2Tecan Austria Ges.m.b.H. Untersbergstrasse 1A, A-5082 Groedig

Cytochrome P450s (CYP 450) and monoamine oxidases (MAO) are critical for the biotransformation of drug compounds. Adverse affects of test compounds on these enzymes often result in drug-drug interactions, leading to off-target levels of drugs within the body. Promega and Tecan have developed a complete automated solution for the profiling of test compounds in dose response format against CYP 450 and MAO. Superior luminescent metabolism assays for CYP 1A2, 2C9, 3A4, 2C19, 2D6, and MAO A are combined with Tecan automation to bring a fully automated, walkaway solution to the ADME screener.

Document Icon Download the poster PDF (227kb)

  • Part# PS032
  • Printed in USA.

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.